 |
|
|
|
|
|
 |
Cancer |
|
|
| Title |
 |
Publication Date |
 |
Price |
|
|
|
|
MarketWatch: Cancer
|
October 2008 |
£105 |
Cancer Drug Resistance
2008
|
September 2008 |
£1675 |
Currently Druggable in Prostate Cancer
A Drug Target Competitive Analysis
|
September 2008 |
£1310 |
Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
|
August 2008 |
£1310 |
Global Cancer Treatment Forecast to 2012
|
August 2008 |
£535 |
Cancer Personalized Medicine 2008
|
July 2008 |
£2425 |
Cytology and HPV Testing World Markets
|
July 2008 |
£2290 |
Cancer Stem Cells
Emerging Therapeutic, Diagnostic and Market Opportunities (2008)
|
June 2008 |
£1599 |
Cancer Antibodies
Competitive Positioning for Success
|
June 2008 |
£1655 |
Cancer Vaccines: Aim and Shoot
|
May 2008 |
£1655 |
Cancer Therapeutics Markets
|
May 2008 |
£2290 |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
|
April 2008 |
£2290 |
Cancer Diagnostic Testing World Markets
|
April 2008 |
£2290 |
Cancer Cell Therapy Markets
|
March 2008 |
£2290 |
The Worldwide Market for Cancer Diagnostics
3rd Edition
|
March 2008 |
£2690 |
Cardiac Toxicity
|
March 2008 |
£1495 |
Textbook of Lung Cancer
|
March 2008 |
£115 |
Treatment Methods for Early and Advanced Prostate Cancer
|
March 2008 |
£99 |
ESMO Handbook of Cancer Prevention
European Society for Medical Oncology Handbooks
|
February 2008 |
£22.5 |
Reflectance Confocal Microscopy of Cutaneous Tumors
An Atlas with Clinical, Dermoscopic and Histological Correlations
|
January 2008 |
£129.95 |
The Cancer Market Outlook to 2012
|
January 2008 |
£1995 |
Stakeholder Opinions: Head and Neck Cancer
Innovatives to Change the Face of Treatment
|
November 2007 |
£2005 |
Who's Developing What in New Cancer Drugs 2006?
|
November 2007 |
£495 |
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
|
November 2007 |
£3125 |
Pipeline Insight Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
|
October 2007 |
£3010 |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
|
October 2007 |
£7600 |
Multiple Myeloma
|
October 2007 |
£105 |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
Cancer Vaccine Developments to 2011
|
September 2007 |
£1296 |
Decoding Big Pharmas R&D Strategy in Oncology
|
September 2007 |
£3125 |
Neurological Complications of Systemic Cancer
|
September 2007 |
£115 |
Prognostic and Predictive Factors in Gynecologic Cancers
|
September 2007 |
£55 |
Hereditary Breast Cancer
|
September 2007 |
£105 |
Cancer-Associated Thrombosis
|
August 2007 |
£115 |
Skull Based Tumors
|
August 2007 |
£230 |
Image-Guided Radiotherapy of Lung Cancer
|
August 2007 |
£130 |
Analytical Tool - Targeted Therapeutics: Melanoma
|
July 2007 |
£2635 |
Melanoma - Targeted Therapeutics
|
July 2007 |
£1655 |
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
|
July 2007 |
£7600 |
Stakeholder Opinions: Primary Brain Cancer
Temozolomide Turns Heads
|
July 2007 |
£2005 |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1545 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
July 2007 |
£4400 |
Clinical Pathology of Urological Tumours
|
July 2007 |
£125 |
Antibody Drug Target Atlas in Oncology
|
June 2007 |
£2915 |
China Anti-tumor Drugs Market Report
2007
|
June 2007 |
£200 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£4400 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£4400 |
Renal Cancer Drug Pipeline Update 2007
|
May 2007 |
£1275 |
Hematological Cancers Drug Pipeline Update 2006
|
May 2007 |
£1700 |
Apoptosis in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1275 |
Non-Antibody Based Cancer Vaccines: Drug Pipeline Update 2006
Drug Pipeline Update 2007
|
May 2007 |
£1275 |
Liver Cancer Drug Pipeline Update 2007
|
May 2007 |
£850 |
Lymphoma Drug Pipeline Update 2006
|
May 2007 |
£1275 |
Prostate Cancer - A Therapeutic & Competitive Insight
Drug Pipeline Update 2007
|
May 2007 |
£1275 |
Leukemia Drug Pipeline Update 2006
|
May 2007 |
£1275 |
Analytical Tool – Hematological Cancers
|
May 2007 |
£5055 |
Bladder Cancer Drug Pipeline Update 2007
|
May 2007 |
£850 |
Analytical Tool: Lymphoma Therapeutics & Competitive Insights
|
May 2007 |
£2635 |
Analytical Tool: Competitive Outlook on Cancer Vaccines
|
May 2007 |
£2635 |
Melanoma Drug Pipeline Update 2007
|
May 2007 |
£1275 |
Antibodies in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1275 |
Ovarian Cancer Drug Pipeline Update 2007
|
May 2007 |
£1275 |
Pancreatic Cancer Drug Pipeline Update 2007
|
May 2007 |
£1275 |
Lung Cancer Drug Pipeline Update 2006
|
May 2007 |
£1275 |
Analytical Tool: Analysis of Cancer Immunotherapy
The World Guide
|
May 2007 |
£4205 |
CRC Drug Pipeline Update 2005
|
May 2007 |
£1275 |
Analytical Tool: Breast Cancer R&D Comprehensive Guide
|
May 2007 |
£2635 |
Analytical Tool: Apoptosis
Promise or deception?
|
May 2007 |
£2635 |
Analytical Tool - Leukemia Therapeutics & Competitive Insights
|
May 2007 |
£2635 |
Analytical Tool: Prostate Cancer
A Therapeutic & Competitive Insight
|
May 2007 |
£2635 |
Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology
|
May 2007 |
£2635 |
Vascular Targeting and Anti-angiogenesis in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1275 |
Immunotherapy in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1700 |
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2006
Drug Pipeline Update 2007
|
May 2007 |
£1275 |
Breast Cancer Drug Pipeline Update 2006
|
May 2007 |
£1275 |
Analytical Tool: Current & Future Lung Cancer Therapeutics
|
May 2007 |
£2635 |
Lung Cancer
Translational and Emerging Therapies
|
May 2007 |
£100 |
Brain Cancer Drug Pipeline Update 2007
|
May 2007 |
£1910 |
Global Cancer Focus Company Directory
|
April 2007 |
£1655 |
Non-Small Cell Lung Cancer Drug Pipeline Update 2007
|
April 2007 |
£1275 |
Targeted Therapeutics in Non-Small Cell Lung Cancer
|
April 2007 |
£1655 |
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma
Limited R&D activity provides opportunity for early-phase pipeline drugs
|
March 2007 |
£2005 |
Immunotherapy of Cancer
|
March 2007 |
£3265 |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
Cancer Therapeutics: The Worldwide Market
The Worldwide Market , 2nd Editon
|
February 2007 |
£2690 |
World market for cancer vaccines 2007-2012
|
January 2007 |
£1999 |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£5905 |
Stakeholder Opinions: Melanoma
Lucrative commercial opportunities persist
|
December 2006 |
£2005 |
Pipeline Insight: Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
|
December 2006 |
£6000 |
Stakeholder Opinions: Gynecological Cancers
Niche opportunities in advanced disease
|
December 2006 |
£2005 |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4205 |
Stakeholder Insight: Pricing and Reimbursement in Oncology
Do payers believe oncology drugs offer good value?
|
December 2006 |
£6000 |
Competitive Outlook on Apoptosis in Oncology
|
December 2006 |
£1655 |
Cancer Market Trends 2006 - 2010
Key market forecasts and growth opportunities
|
December 2006 |
£1050 |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£4400 |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
Stakeholder Insight: Non-Small Cell Lung Cancer
The need for greater product differentiation in an increasingly crowded market
|
November 2006 |
£8000 |
Regulator Perceptions in Cancer
Evolving opinions about the oncology drug approval process
|
November 2006 |
£1000 |
Emerging Cancer Vaccine Market, The
2nd Edition
|
November 2006 |
£2355 |
Hematological Cancers - A Therapeutic & Competitive Insight
|
October 2006 |
£2505 |
Colorectal Cancer: Pipeline/Commercial Insight
Shaping the future dynamics of colorectal cancer management
|
October 2006 |
£8000 |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£2930 |
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
|
October 2006 |
£1655 |
Stakeholder Insight: Supportive Care in Cancer Treatment
Some first-generation products proving difficult to dislodge
|
October 2006 |
£8000 |
Leukemia - A Therapeutic & Competitive Insight
|
October 2006 |
£1655 |
The Cancer Market Outlook to 2011
|
October 2006 |
£1495 |
Emerging Opportunities in Cancer Nanomedicine
|
August 2006 |
£995 |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2930 |
Competitive Outlook on Non-Antibody Based Cancer Vaccines
|
August 2006 |
£1655 |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2930 |
What's Hot in Cancer Drug R&D?
|
July 2006 |
£295 |
Commercial Insight Top 20 Cancer Therapeutics
|
July 2006 |
£8695 |
Stakeholder Opinions: Ovarian Cancer
Growing importance as secondary indication for targeted therapies
|
July 2006 |
£2195 |
Analytical Tool: The Commercial Success of Cancer Therapeutic Antibodies
|
June 2006 |
£2635 |
Cancer Biomarkers
Enhancing diagnostic, therapeutic and developmental strategies
|
May 2006 |
£2195 |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
Stakeholder Opinions: Gastric Cancer
Targeted Therapies Home In On a Neglected Tumor Type
|
March 2006 |
£2195 |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£2930 |
Current and Future Therapies for Lung Cancer
A Therapeutic & Competitive Insight
|
March 2006 |
£1655 |
Analytical Tool: Protein Kinase Inhibitors in Oncology
|
February 2006 |
£2635 |
Targeted Cancer Therapies Markets
Sector Snapshot
|
January 2006 |
£335 |
New Concepts in Cancer Therapeutics
|
December 2005 |
£2080 |
World Cancer Market Yearbook 2005
|
December 2005 |
£495 |
Generic Cancer Market
New Legislation and a Wave of Patent Expiries to Transform the Market
|
December 2005 |
£8695 |
Cancer Therapeutics 2006
Market Dynamics and R&D Trends
|
December 2005 |
£1685 |
The Commercial Success of Cancer Therapeutic Antibodies
The Formation of a Second Wave
|
November 2005 |
£1655 |
Superficial Bladder Cancer
Current Management and Future Trends
|
November 2005 |
£1095 |
Stakeholder Insight: Prostate Cancer
A Prostrate Market Waiting for Innovations
|
October 2005 |
£8695 |
Lung cancer: Industry Background Report
List of Companies
|
October 2005 |
£295 |
Apoptosis: Industry Background Report
List of Companies
|
October 2005 |
£345 |
Colorectal Cancer: Industry Background Report
List of Companies
|
October 2005 |
£295 |
Pancreatic Cancer: Industry Background Report
List of Companies
|
October 2005 |
£235 |
Liver Cancer: Industry Background Report
List of Companies
|
October 2005 |
£235 |
Prostate Cancer: Industry Background Report
List of Companies
|
October 2005 |
£345 |
Cancer Diagnostics
Technology and Business Trends
|
October 2005 |
£1945 |
Breast Cancer: Industry Background Report
List of Companies
|
October 2005 |
£345 |
Who's Developing What in New Cancer Drugs 2005?
|
September 2005 |
£495 |
Optimizing Targeted Treatment in Cancer
Negotiating the Challenges to Success
|
September 2005 |
£1000 |
Hematological Cancer Therapeutics
Pipelines and Competition
|
September 2005 |
£2140 |
Cancer Drug Discoveries: Colorectal Cancer
|
August 2005 |
£795 |
Cancer Drug Discoveries: Prostate Cancer
|
August 2005 |
£795 |
Cancer Drug Discoveries: Breast Cancer
|
August 2005 |
£795 |
Cancer Drug Discoveries: Non-Small Cell Lung Cancer
|
August 2005 |
£795 |
Apoptosis: Promise or deception?
|
May 2005 |
£1655 |
Stakeholder Insight: Breast Cancer
Changing Treatment Paradigms for Local and Locally Advanced Breast Cancer
|
April 2005 |
£6000 |
Pipeline Insight: Cancer Vaccines and Cell Therapies
Technical Know How Needs Translation Into Clinical and Commercial Rewards
|
April 2005 |
£6000 |
Vascular Targeting Agents: Emerging Competitors
|
February 2005 |
£1655 |
Cancer Vaccines Fantasy or Future?
|
February 2005 |
£1655 |
The Cancer Market Outlook to 2010
|
January 2005 |
£1495 |
Cancer Market Top 20 Drugs
Supportive Care Grows the Cancer Market
|
January 2005 |
£8000 |
Pancreatic Cancer
Gold Standard Gemcitabine Waiting to be Challenged
|
December 2004 |
£8000 |
Inflammatory Bowel Disease
Efficacy and Compliance Key to Maximizing Patient Share
|
December 2004 |
£8000 |
Cancer Vaccines
Measuring Market Potential
|
October 2004 |
£1010 |
Stakeholder Insight: Local and Locally Advanced Prostate Cancer
|
September 2004 |
£8000 |
Stakeholder Insight: Prostate Cancer Treatment in the USA
|
September 2004 |
£8000 |
Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer
|
September 2004 |
£8000 |
Stakeholder Insight: Prostate Cancer Treatment and Commercial Issues
|
September 2004 |
£8000 |
Immunomodulators in Cancer Therapy
Emerging Products and Markets
|
August 2004 |
£2355 |
Analytical Tool: Competitive Outlook on HCV
|
July 2004 |
£1275 |
Analytical R&D Tool - Analysis of Prostate Cancer R&D
The Complete Guide
|
February 2004 |
£3400 |
|
|
|
|
